Print Friendly, PDF & Email

Myo-Inositol Trispyrophosphate (ITPP) helps red blood cells release oxygen into the body. It also has antioxidant and anti-cancer properties. Learn more about its roles in the body and where to buy it.



Myo-Inositol Trispyrophosphate (ITPP) is an allosteric effector of hemoglobin that increases red blood cells’ ability to release oxygen. This means it increases red blood cells’ ability to release oxygen by binding to another site than the active site where oxygen binds [R].

Oxygen delivery is important for maximal muscle function and activity.

ITPP is able to cross the red blood cell membrane [R].

ITPP is a synthetic compound derived from myoinositol hexakisphosphate, which is normally produced in mammalian cells and has antioxidant and anti-cancer properties [R].

Health Benefits of Myo-Inositol Trispyrophosphate

1) Myo-Inositol Trispyrophosphate Decreases Hypoxia


ITPP’s ability to improve oxygen carrying capacity and delivery makes it a great candidate to decrease hypoxiaHypoxia is the deficiency in oxygen delivery to tissues and it normally encourages angiogenesis (the development of new blood vessels) as well as cancer progression [R].

Hypoxia is bad because tumors with low oxygen levels induce the formation of new blood vessels. This process occurs when Hypoxia-inducible genes, such as VEGF are switched on. Then, human Microvascular Endothelial Cells line up to begin angiogenesis [R].

ITPP blocks the Microvascular Endothelial Cells from lining up because ITPP allows the red blood cells to carry and release enough oxygen to suppress/prevent hypoxic conditions [R].

2) Myo-Inositol Trispyrophosphate Increases Exercise Capacity


ITPP decreases oxygen binding affinity to red blood cells, thus increasing oxygen release to blood [R].

Mice who had heart problems were injected with ITPP. Their red blood cells were able to carry about 22% more p50 O2 than normal mice [R].

ITPP suppresses HIF, indicating that ITPP does increase the availability of oxygen to tissue [R].

It increased the exercise capacity of the mice, due to increased oxygen delivery. This indicates that ITPP can help improve exercise capacity in patients who have suffered from heart failure [R].

ITPP was also able to increase oxygen carrying capacity and delivery in the hemoglobin of normal mice.

Mice were tested using a treadmill before and after ITPP injection. ITPP did increase their exercise capacity [R].

3) Myo-Inositol Trispyrophosphate Can Improve the Effects of Cancer 


A side-effect of Pancreatic Cancer is hypoxia, which leads to chemotherapy resistance and immune system suppression [R].

A study was performed to determine if ITPP can improve normal oxygen function, thus improving the chemotherapy response. Weekly intravenous ITPP injection decreased metastases and tumor growth. Normal oxygen function in the tumor returned and hypoxia decreased [R].

This also led to better immune cell function and better response to chemotherapy [R].

Normal oxygen function was achieved because ITPP normalized the generation of new blood vessels and vascularization [R].

ITPP improved survival rates for mice with colon cancer by decreasing the spread of cancer cells and stimulating the expression of the Cdx2 gene, which is usually decreased in tumors due to hypoxia [R].


  • Although carrying capacity remained around the same at p100, the increase at p50 indicates that more oxygen is released at low oxygen tissue [R].
  • The effects lasted for the same amount of time as the half-life of  a red blood cell, showing that the effects last for a long time [R].
  • Preventing tumor neovascularization is a beneficial treatment to halt the spread of cancer cells and metastases [R].
  • Myo-inositol tris pyrophosphate (ITPP), endothelial cells (ECs) do not align, i.e., do not form “vessel”-like structures. The “loaded” RBCs are capable of releasing under hypoxia more oxygen than their “normal” counterparts [R].
  • Incubation with ITPP enhances the capacity of Hb to release bound oxygen, leading to higher oxygen tension in the hypoxic environment, thus inhibiting hypoxia-induced angiogenesis. These observations suggest a potential in vivo role of ITPP-loaded, “low-O2-affinity” RBCs in cancer therapy [R].


Athletes may use ITPP because it increases exercise capacity. However, this is a type of doping. ITPP is banned in professional sports [R].

Buy Myo-Inositol Trispyrophosphate (ITPP)

FDA Compliance

The information on this website has not been evaluated by the Food & Drug Administration or any other medical body. We do not aim to diagnose, treat, cure or prevent any illness or disease. Information is shared for educational purposes only. You must consult your doctor before acting on any content on this website, especially if you are pregnant, nursing, taking medication, or have a medical condition.


1 Star2 Stars3 Stars4 Stars5 Stars (7 votes, average: 2.71 out of 5)


  • Eddie barker

    Can you tell me what the half life of itpp would be?

  • Dr Chris Bruno

    I looked at the website but the cas # structure and physical name cannot be found at sigma Aldrich. I believe this to be a bogus site.

  • Brandon

    Where can you get it?

  • Brandon

    Where’s the best source to purchase this stuff? I have found it at and I’m curious to hear your opinion.

  • ninetynine

    It has oral bioavailability. Endurance improvements in one study were about 60% if injected, and about 35% for the same dose oral. If you take a higher oral dose, it should saturate better. You could also try sublingual — it usually absorbs better than oral. Anecdotally people seem to be using about 100mg of it. The effects last as long as red blood cells themselves do — several weeks. Some people re-dose on a few successive days also, probably again to improve saturation. Then skip it for a couple of weeks before re-dosing again to buff up any RBCs produced since the last time.

  • Francisco

    Does it have to be injected or does it have any oral bioavailability?

  • Leave a Reply

    Your email address will not be published. Required fields are marked *